ImmunoGen
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Cash used in financing activities reached the amount of $27,554,000 last year. Net change in cash is therefore -$203,612,000.
Cash Flow
| 2016 | -124.47M | -10.37M | 101.76M |
|---|---|---|---|
| 2016 | -142.64M | -6.65M | 96.97M |
| 2017 | 7.64M | -1.11M | 100.61M |
| 2018 | -166.42M | -5.24M | 166.81M |
| 2019 | -88.36M | -533K | 2.87M |
| 2020 | -78.62M | 509K | 195.74M |
| 2021 | -229.80M | -1.36M | 355.74M |
| 2022 | -229.80M | -1.36M | 27.55M |
0A8K.L Cash Flow Statement (2015 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 478.75M | 478.75M | 176.22M | 262.25M | 267.10M | 159.96M | 278.10M | 278.10M |
Operating activities | ||||||||
Net income | -222.92M | -222.92M | -44.37M | -104.13M | -168.84M | -96.01M | -156.73M | -144.81M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 1.78M | 1.78M | 2.10M | 4.02M | 7.41M | 5.96M | 6.01M | 5.32M |
Stock-based compensation expense | 25.61M | 25.61M | 14.32M | 14.16M | 16.80M | 11.32M | 20.12M | 22.24M |
| Deferred income tax benefit | 25.61M | 25.61M | 14.32M | 14.16M | 16.80M | 11.32M | 20.12M | 22.24M |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | -8.12M | -8.12M | 7.46M | -5.79M | 948K | -623K | -7.11M | 4.20M |
Inventories | -16.19M | -16.19M | 10.22M | -11.87M | 1.03M | 1.15M | -655K | 2.02M |
Accounts payable | 26.73M | 26.73M | -819K | -1.04M | 2.66M | 771K | 0 | 2.64M |
Cash generated by operating activities | -229.80M | -229.80M | -78.62M | -88.36M | -166.42M | 7.64M | -142.64M | -124.47M |
Investing activities | ||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -1.36M | -1.36M | -917K | -2.84M | -5.24M | -1.11M | -6.65M | -10.37M |
Acquisitions Net | 0 | 0 | 1.42M | 2.31M | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -1.36M | -1.36M | 509K | -533K | -5.24M | -1.11M | -6.65M | -10.37M |
Financing activities | ||||||||
Common Stock Issued | 25.64M | 356.84M | 0 | 2.87M | 0 | 0 | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | -1.1M | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 27.55M | 355.74M | 195.74M | 2.87M | 166.81M | 100.61M | 96.97M | 101.76M |
Net Change In Cash | -203.61M | -203.61M | 117.63M | -86.02M | -4.85M | 107.14M | -33.08M | -33.08M |
Cash at end of period | 275.13M | 275.13M | 293.85M | 176.22M | 262.25M | 267.10M | 245.02M | 245.02M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |